Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4819668 | 0.89 | BRD4 (0.57) | BRD4CREBBPTACR1CNR2ACP3 | |
| SCHEMBL11914197 | 0.87 | ALDH1A1 (0.46) | BRD4CREBBPTACR1ACHEAOC3 | |
| SCHEMBL13027665 | 0.83 | TACR1 (0.46) | BRD4CREBBPTACR1CNR2ACP3 | |
| SCHEMBL30655591 | 0.81 | BRD4 (0.51) | BRD4CREBBPTACR1CNR2PDE10A | |
| SCHEMBL27686957 | 0.80 | AOC3 (0.54) | BRD4CREBBPCNR2AOC3CA4 | |
| SCHEMBL477338 | 0.80 | AOC3 (0.54) | BRD4CREBBPCNR2AOC3CA4 | |
| SCHEMBL4428549 | 0.79 | TACR1 (0.48) | BRD4CREBBPTACR1ACHEACP3 | |
| SCHEMBL477389 | 0.77 | ACP3 (0.61) | CNR2ACP3CA4L3MBTL1 | |
| SCHEMBL477621 | 0.77 | ACP3 (0.61) | CNR2ACP3CA4L3MBTL1 | |
| SCHEMBL477466 | 0.77 | ACP3 (0.61) | CNR2ACP3CA4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| EP-2074102-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | ESR1, GPER1, ESR2 | BRD4 1096/4885CREBBP 2660/4885TACR1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.